NCT02000037

Brief Summary

The study aim is to Assess the Effect of an IR Reflexotherapy on Overweight and Class I Obese People.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
87

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2013

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 18, 2013

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

November 26, 2013

Completed
7 days until next milestone

First Posted

Study publicly available on registry

December 3, 2013

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 28, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 28, 2016

Completed
Last Updated

December 8, 2022

Status Verified

December 1, 2022

Enrollment Period

2.3 years

First QC Date

November 26, 2013

Last Update Submit

December 6, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Weight changes after 12 months compared to a dietary care (associated with physical activity advice) dispensed by a professional.

    12 months

Secondary Outcomes (12)

  • Effect of infrared (IR) reflexotherapy on weight changes.

    3, 12 and 18 months

  • Effect of IR reflexotherapy combined with a dietary care (and physical activity advises) dispensed by a professional on the weight changes.

    3, 12 and 18 months.

  • Effect of infrared (IR) reflexotherapy on waist size.

    3, 12 and 18 months

  • Effect of IR reflexotherapy combined with a dietary care (and physical activity advises) dispensed by a professional on the waist siez.

    3, 12 and 18 months.

  • Effect of infrared (IR) reflexotherapy on dietary habits.

    3, 12 and 18 months

  • +7 more secondary outcomes

Study Arms (3)

Dietary care

ACTIVE COMPARATOR

Treatment is composed of a dietary care (with advices on physical activity) given by a professional (dietician of the Nutrition Department of the Institut Pasteur de Lille).

Behavioral: Dietary care

IR reflexotherapy + dietary care

EXPERIMENTAL

Treatment is composed of : * IR reflexotherapy sessions given by a trained professional ; * dietary care (with advices on physical activity) given by a professional (dietician of the Nutrition Department of the Institut Pasteur de Lille).

Device: IR ReflexotherapyBehavioral: Dietary care

IR Reflexotherapy

EXPERIMENTAL

Treatment is composed of IR reflexotherapy sessions given by a trained professional.

Device: IR Reflexotherapy

Interventions

18 IR reflexotherapy sessions : * Once a week for 12 weeks at the beginning of the study * Once a week for 3 weeks, 9 months after the beginning of the study * Once a week for 3 weeks, 15 months after the beginning of the study

IR ReflexotherapyIR reflexotherapy + dietary care
Dietary careBEHAVIORAL

Dietary consultation 1, 2, 3, 6, 9, 12, 15 and 18 months after the beginning of the study

Dietary careIR reflexotherapy + dietary care

Eligibility Criteria

Age30 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • BMI between 27 and 35 kg/m2 (included),
  • Aged 30 to 60 years old (included),
  • Stable weight: no variation of 3 kg in the las 3 months,
  • Signed the consent form,
  • Able to follow the study,
  • Health insured.

You may not qualify if:

  • History of coronary disease (in the last 6 months),
  • Progressive illness at the time of the study (cancer, neurodegenerative disease...),
  • Diabetics (treated or not),
  • Fasting blood total cholesterol equal or over 2.5 g/L (treated or not),
  • Fasting blood triglycerides equal or over 2.0 g/L (treated or not),
  • Fasting blood glucose equal or over 1.26 g/L,
  • Peripheral neuropathy (polyneuritis, diabetic neuropathy) or central neuropathy (hemiplegia),
  • Infectious cutaneous condition or allergies (to the contact point of the device),
  • History of stroke,
  • Severe heart disease,
  • Epilepsy,
  • Reduced motility,
  • Diagnosed eating disorder,
  • Followed a diet in the last 90 days in order to lose weight,
  • Took weight loss assistance drug (Orlistat) in the last month or is likely to take one during the study,
  • +12 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NutrInvest - Institut Pasteur de Lille

Lille, Nord, 59019, France

Location

Study Officials

  • Jean-Michel LECERF, MD

    Institut Pasteur de Lille

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical doctor specialized in endocrinology and metabolic diseases

Study Record Dates

First Submitted

November 26, 2013

First Posted

December 3, 2013

Study Start

October 18, 2013

Primary Completion

January 28, 2016

Study Completion

January 28, 2016

Last Updated

December 8, 2022

Record last verified: 2022-12

Locations